CNR Institutional Research Information System

SANTORO, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.279
NA - Nord America 1.405
SA - Sud America 451
EU - Europa 450
AF - Africa 35
OC - Oceania 5
Totale 4.625
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.341
SG - Singapore 985
CN - Cina 531
BR - Brasile 371
HK - Hong Kong 263
VN - Vietnam 223
FR - Francia 126
NL - Olanda 87
KR - Corea 79
IT - Italia 53
BD - Bangladesh 45
DE - Germania 45
AR - Argentina 41
JP - Giappone 39
FI - Finlandia 34
CA - Canada 31
GB - Regno Unito 26
IN - India 24
MX - Messico 19
EC - Ecuador 17
IL - Israele 12
ZA - Sudafrica 12
ES - Italia 11
ID - Indonesia 11
UA - Ucraina 11
IQ - Iraq 9
SE - Svezia 8
AT - Austria 7
CO - Colombia 7
TR - Turchia 7
KZ - Kazakistan 6
PL - Polonia 6
RU - Federazione Russa 6
OM - Oman 5
PH - Filippine 5
SA - Arabia Saudita 5
SC - Seychelles 5
TN - Tunisia 5
UZ - Uzbekistan 5
VE - Venezuela 5
IE - Irlanda 4
LB - Libano 4
MA - Marocco 4
PK - Pakistan 4
PT - Portogallo 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
BG - Bulgaria 3
CL - Cile 3
CR - Costa Rica 3
LT - Lituania 3
PY - Paraguay 3
SK - Slovacchia (Repubblica Slovacca) 3
TW - Taiwan 3
BN - Brunei Darussalam 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GT - Guatemala 2
HU - Ungheria 2
JM - Giamaica 2
KE - Kenya 2
LV - Lettonia 2
NP - Nepal 2
PE - Perù 2
TT - Trinidad e Tobago 2
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
CY - Cipro 1
DK - Danimarca 1
EE - Estonia 1
EG - Egitto 1
ET - Etiopia 1
GU - Guam 1
HN - Honduras 1
HR - Croazia 1
IR - Iran 1
IS - Islanda 1
JO - Giordania 1
LK - Sri Lanka 1
LY - Libia 1
MY - Malesia 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
RO - Romania 1
SR - Suriname 1
TH - Thailandia 1
UY - Uruguay 1
Totale 4.625
Salva come PNG Salva come JPEG
Città #
Singapore 565
Santa Clara 552
Hong Kong 261
Hefei 189
San Jose 117
Beijing 106
Lauterbourg 105
Ashburn 102
Seoul 79
Ho Chi Minh City 76
Hanoi 56
Los Angeles 51
New York 35
Helsinki 34
São Paulo 28
Dallas 27
Tokyo 25
Frankfurt am Main 21
Buffalo 17
Belo Horizonte 13
Minamishinagawa 12
Rio de Janeiro 12
Da Nang 11
Atlanta 10
Brasília 10
Milan 10
Chicago 9
Haiphong 9
Bengaluru 8
Düsseldorf 8
Falkenstein 8
Johannesburg 8
Montreal 8
Orem 8
Dublin 7
Naples 7
Portsmouth 7
Denver 6
Dhaka 6
Guayaquil 6
Madrid 6
Ninh Bình 6
Quận Bình Thạnh 6
Stockholm 6
Baghdad 5
Boardman 5
Buenos Aires 5
Campinas 5
Houston 5
Mexico City 5
Uberaba 5
Uberlândia 5
Washington 5
Biên Hòa 4
Brooklyn 4
Cleveland 4
Elk Grove Village 4
Hangzhou 4
Manchester 4
Newark 4
Phoenix 4
Quito 4
Santo André 4
Shanghai 4
Sumaré 4
Tashkent 4
Warsaw 4
Acalanes Ridge 3
Blumenau 3
Boston 3
Chennai 3
Delhi 3
Diadema 3
Goiânia 3
Itaquaquecetuba 3
Jacksonville 3
Jeddah 3
Kyiv 3
London 3
Lấp Vò 3
Maceió 3
Medford 3
Osasco 3
Paris 3
Piracicaba 3
Piscataway 3
Porto Alegre 3
Portoviejo 3
Richmond 3
Riverside 3
San Francisco 3
Toronto 3
Vienna 3
Agawam 2
Almaty 2
Amsterdam 2
Andorinha 2
Ankara 2
Araraquara 2
Araruama 2
Totale 2.846
Salva come PNG Salva come JPEG
Nome #
Point mutation in GRIM-19: a new genetic lesion in Hurthle cell thyroid carcinomas. 87
Indoleamine 2,3-Dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment 86
The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. 85
Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase. 81
ZD6474, an Orally Available Inhibitor of KDR Tyrosine Kinase Activity, Efficiently Blocks Oncogenic RET Kinases. 77
A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. 77
The b-catenin Axis Integrates Multiple Signals Downstream From RET/PTC and Leads to Cell Proliferation. 71
Attacking cancer with molecularly targeted agents Editorial overview 68
Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma 64
UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. 60
CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1 59
BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. 58
Impairment of the p27kip1 function enhances thyroid carcinogenesis in TRK-T1 transgenic mice 57
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. 53
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. 53
Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27(kip1). 52
Overexpression of proteins HMGA1 induces cell cycle deregulation and apoptosis in normal rat thyroid cells. 52
Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. 52
CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model. 52
The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. 50
CD44 proteolysis increases CREB phosphorylation and sustains proliferation of thyroid cancer cells. 50
Tumour Suppressor Role of the CL2/DRO1/CCDC80 Gene in Thyroid Carcinogenesis. 50
The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane 49
Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies 49
Genetics: The genomic landscape of papillary thyroid carcinoma 47
Identification of novel small molecule inhibitors of oncogenic RET kinase 47
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer 47
The highly malignant phenotype of anaplastic thyroid carcinoma cell lines is recessive. 46
Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma 46
Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. 46
Thyroid cell transformation requires the expression of the HMGA1 proteins. 45
The rat tyrosine phosphatase eta increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue. 45
Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. 45
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: Design, synthesis and evaluation 45
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. 45
A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability. 44
XB130 mediates cancer cell proliferation and survival through multiple signaling events downstream of Akt. 44
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. 44
Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia 44
RET/PTC activation in human thyroid carcinomas 44
Ret-mediated mitogenesis requires Src kinase activity 43
Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. 43
TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype. 43
Oncogenic rearrangements driving ionizing radiation-associated human cancer 42
RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma 42
Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. 42
Block of c-myc expression by antisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines 41
BRAF is a therapeutic target in aggressive thyroid carcinoma. 41
RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block. 41
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. 40
Receptor tyrosine kinase inhibitors in thyroid cancer. 40
XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway. 40
CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas. 39
A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts. 39
The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway. 38
A new mechanism of BRAF activation in human thyroid papillary carcinomas. 38
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. 38
RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. 37
FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. 37
Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. 37
Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma. 37
Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. 36
OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome. 36
Critical role of the HMGI(Y) proteins in adipocytic cell growth and differentiation. 35
Pros and cons of cellular studies in developing new drugs for thyroid cancers. 34
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. 34
Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. 34
Novel candidate genes of thyroid tumourigenesis identified in Trk-T1 transgenic mice. 33
Central role of RET in thyroid cancer 33
SOD3 Decreases Ischemic Injury Derived Apoptosis through Phosphorylation of Erk1/2, Akt, and FoxO3a. 33
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. 32
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. 32
Mast cells have a protumorigenic role in human thyroid cancer. 31
Low frequency of p53 mutations in human thyroid tumors: p53 and Ras mutation in two aut of fifty-six thyroid carcinomas 30
Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival 30
Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes 29
Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. 29
Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas 29
Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential 29
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture 29
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. 29
Rat protein tyrosine phosphatase eta physically interacts with the PDZ domains of syntenin. 29
BAY 43-9006 inhibition of oncogenic RET mutants. 29
Minireview: RET: normal and abnormal functions 28
The highly malignant phenotype of anaplastic thyroid carcinoma cell lines is recessive 28
RAI(ShcC/N-Shc)-dependent recruitment of GAB 1 to RET oncoproteins potentiates PI 3-K signalling in thyroid tumors. 28
Overexpression of the HIP gene coding for a Heparin/Heparan Sulfate-binding protein in human thyroid carcinomas 27
Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. 27
RET/PTC oncogene activation is an early event in thyroid carcinogenesis 26
Glial cell line-Derived Neurotrophic Factor differentially stimulates Ret mutants associated with the Multiple Endocrine Neoplasia type 2 syndromes and Hirschsprung's disease 26
Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenic mechanism of multiple endocrine neoplasia type 2B 26
Receptor tyrosine kinases as targets for anticancer therapeutics. 26
Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. 25
The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. 25
A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma. 25
Different mutations of the RET gene cause different human tumoral diseases 25
New therapeutic approaches to treat medullary thyroid carcinoma. 25
Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. 24
RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho. 24
Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): Evidence for a divergence of the ERKs and JNKs pathways induced by Ret 24
Totale 4.188
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.477
article - articoli 15.477
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.954
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202421 0 0 0 0 0 0 0 0 5 0 16 0
2024/20251.868 6 7 136 68 509 70 19 114 43 128 417 351
2025/20262.631 112 261 254 406 508 141 368 138 127 149 92 75
2026/2027114 114 0 0 0 0 0 0 0 0 0 0 0
Totale 4.634